Join us for a discussion of data showcasing the validity and utility of using circulating tumor DNA (ctDNA) across neoadjuvant, post-surgical / adjuvant, and metastatic settings, including:

• How ctDNA clearance could supplement pCR to better predict patient outcomes during and after neoadjuvant therapy
• How serial monitoring of ctDNA allows for early identification of patients at risk of progression in the post-surgical setting
• How change in ctDNA within 3 cycles of treatment can be a strong predictor of future outcomes in the metastatic setting

We will cover the latest clinical data from 2021 and 2020 publications and presentations (including SABCS and Nature), prospective studies leveraging ctDNA to enroll breast cancer patients, as well as discuss future implications for clinical trials and clinical practice